Anticoagulant Activities of Indobufen, an Antiplatelet Drug
Tóm tắt
Indobufen is a new generation of anti-platelet aggregation drug, but studies were not sufficient on its anticoagulant effects. In the present study, the anticoagulant activity of indobufen was determined by monitoring the activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) in rabbit plasma. We evaluated the anticoagulant mechanisms on the content of the platelet factor 3,4 (PF3,4), and the coagulation factor 1, 2, 5, 8, 10 (FI, II, V, VIII, X) in rabbits, as well as the in vivo bleeding time and clotting time in mice. The pharmacodynamic differences between indobufen and warfarin sodium, rivaroxaban, and dabigatran were further studied on thrombus formation and the content of FII and FX in rats. Animal experiments showed that intragastric-administrated indobufen can significantly reduce the APTT, PT, TT, PF3, FI, II, V, VIII, and X plasma contents. Its inhibitory effect on plasma FII was better than thrombin inhibitor dabigatran with effect on FX better than FXa inhibitor rivaroxaban. These results suggest that indobufen has some anticoagulant effects as strong as some conventional anticoagulants. The mechanism may be related to both exogenous and endogenous coagulation system.
Từ khóa
Tài liệu tham khảo
Jin, 2016, Potential blood clotting factors and anticoagulants, Biomed. Pharmacother., 84, 356, 10.1016/j.biopha.2016.09.057
Ryu, 2013, Anticoagulant and antiplatelet activities of artemisia princeps pampanini and its bioactive components, Prev. Nutr. Food Sci., 18, 181, 10.3746/pnf.2013.18.3.181
Butenas, 2002, Blood coagulation, Biochemistry, 67, 3
Prevention, 2000, The italian guidelines for stroke prevention, Neurol. Sci., 21, 5, 10.1007/s100720070112
Schuijt, 2013, Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: Lessons from a tick salivary protein, Circulation, 128, 254, 10.1161/CIRCULATIONAHA.113.003191
Qiu, 2017, Capture of anti-coagulant active ingredients from Moutan Cortex by platelet immobilized chromatography and evaluation of anticoagulant activity in rats, Biomed. Pharmacother., 95, 235, 10.1016/j.biopha.2017.08.051
Vinazzer, 1980, Clinical pharmacology studies with indobufen (K 3920): Inhibitor of platelet aggregation, J. Clin. Pharmacol., 20, 316, 10.1177/009127008002000502
Wiseman, 1992, Indobufen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease, Drugs, 44, 445, 10.2165/00003495-199244030-00009
Posma, 2016, Coagulation and non-coagulation effects of thrombin, J. Thromb. Haemost., 14, 1908, 10.1111/jth.13441
Coleman, 2012, Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation, Int. J. Clin. Pract., 66, 53, 10.1111/j.1742-1241.2011.02809.x
Eligini, 2006, Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism, Cardiovasc. Res., 69, 218, 10.1016/j.cardiores.2005.07.013
Morocutti, 1997, Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators, Stroke, 28, 1015, 10.1161/01.STR.28.5.1015
Patrono, 2008, Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th edition), Chest, 133, 199S, 10.1378/chest.08-0672
Mannucci, 1987, Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk, Thromb. Res., 48, 417, 10.1016/0049-3848(87)90399-9
Grasselli, 1987, In vitro and ex vivo effects of indobufen on red blood cell deformability, Eur. J. Clin. Pharmacol., 32, 207, 10.1007/BF00542198
Naithani, 2008, Bilateral vitreous hemorrhage in a child due to isolated platelet factor 3 availability defect, J. AAPOS, 12, 203, 10.1016/j.jaapos.2007.09.013
Kowalska, 2010, Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis, Thromb. Res., 125, 292, 10.1016/j.thromres.2009.11.023
Lord, 2017, Platelet factor 4 binds to vascular proteoglycans and controls both growth factor activities and platelet activation, J. Biol. Chem., 292, 4054, 10.1074/jbc.M116.760660
Heemskerk, 2013, Platelet-based coagulation: different populations, different functions, J. Thromb. Haemost., 11, 2, 10.1111/jth.12045
Samama, 2011, The mechanism of action of rivaroxaban—An oral, direct Factor Xa inhibitor—Compared with other anticoagulants, Thromb. Res., 127, 497, 10.1016/j.thromres.2010.09.008
Vinholt, 2017, Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner, J. Thromb. Thrombolysis., 44, 216, 10.1007/s11239-017-1512-2
Xu, 2017, Bleeding effected by direct oral anticoagulants study, g., direct oral anticoagulant- or warfarin-related major bleeding: Characteristics, reversal strategies, and outcomes from a multicenter observational study, Chest, 152, 81, 10.1016/j.chest.2017.02.009
Stratton, 1997, Chronic atrial fibrillation: Selection of antithrombotic therapy, Card. Electrophysiol. Rev., 1, 35, 10.1023/A:1009903216196
Carrieri, 1987, Antithrombotic effect of indobufen in an experimental model of arterio-arterial microanastomosis in the rat, Thromb. Res., 45, 195, 10.1016/0049-3848(87)90187-3
Lee, 2016, Comparison of aspirin and indobufen in healthy volunteers, Platelets, 27, 105
Group, 2001, Long term anticoagulation or antiplatelet treatment, BMJ, 323, 235
Smith, 2015, How it all starts: Initiation of the clotting cascade, Crit. Rev. Biochem. Mol. Biol., 50, 326, 10.3109/10409238.2015.1050550
Lee, 2015, Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin, Arch. Pharm. Res., 38, 893, 10.1007/s12272-014-0410-9
Triplett, 2000, Coagulation and bleeding disorders: review and update, Clin. Chem., 46, 1260, 10.1093/clinchem/46.8.1260
Di, 2017, Old and new oral anticoagulants: Food, herbal medicines and drug interactions, Blood Rev., 31, 193, 10.1016/j.blre.2017.02.001
Molina, 2014, A quantitative and humane tail bleeding assay for efficacy evaluation of antihaemophilic factors in haemophilia A mice, Haemophilia, 20, e392, 10.1111/hae.12484
Kaku, 2013, Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis, Eur. J. Pharmacol., 699, 40, 10.1016/j.ejphar.2012.11.026
Greene, 2010, Animal models subcommittee of the, s.; standardization committee of the, i., towards a standardization of the murine tail bleeding model, J. Thromb. Haemost., 8, 2820, 10.1111/j.1538-7836.2010.04084.x
Umar, 2015, Effect of traditional Uyghur medicine abnormal Savda Munziq extract on rabbit platelet aggregation in vitro and rat arteriovenous shunt thrombosis in vivo, J. Ethnopharmacol., 159, 184, 10.1016/j.jep.2014.11.006